Autologous followed by allogeneic versus tandem-autologous transplantation in high-risk, newly diagnosed multiple myeloma: a systematic review and meta-analysis

References

• Jakubowiak AJ, Kumar S, Medhekar R, et al. Daratumumab improves depth of response and progression-free survival in transplant-ineligible, high-risk, newly diagnosed multiple myeloma. Oncologist. 2022 Jul 5;27(7):e589–e596. doi:10.1093/oncolo/oyac067
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022 Aug;97(8):1086–1107. doi:10.1002/ajh.26590
   PubMed Web of Science ®Google Scholar
• Marcon C, Simeon V, Deias P, et al. Experts’ consensus on the definition and management of high risk multiple myeloma. Front Oncol. 2022;12:1096852. doi:10.3389/fonc.2022.1096852
   PubMed Web of Science ®Google Scholar
• Giri S, Grimshaw A, Bal S, et al. Evaluation of daratumumab for the treatment of multiple myeloma in patients with high-risk cytogenetic factors: a systematic review and meta-analysis. JAMA Oncol. 2020 Nov 1;6(11):1759–1765. doi:10.1001/jamaoncol.2020.4338
   PubMed Web of Science ®Google Scholar
• Barila G, Bonaldi L, Grassi A, et al. Identification of the true hyperdiploid multiple myeloma subset by combining conventional karyotyping and FISH analysis. Blood Cancer J. 2020 Feb 17;10(2):18. doi:10.1038/s41408-020-0285-6
   PubMed Web of Science ®Google Scholar
• Manier S, Salem KZ, Park J, et al. Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol. 2017 Feb;14(2):100–113. doi:10.1038/nrclinonc.2016.122
   PubMed Web of Science ®Google Scholar
• Derman BA, Kosuri S, Jakubowiak A. Knowing the unknowns in high risk multiple myeloma. Blood Rev. 2022 Jan;51:100887. doi:10.1016/j.blre.2021.100887
   PubMed Web of Science ®Google Scholar
• Mohyuddin GR, Sigle M, Chandrasekar VT, et al. Impact of anti-CD38 therapy in multiple myeloma with high-risk cytogenetics: systematic review and meta-analysis. Leuk Lymphoma. 2020 Oct;61(10):2519–2522. doi:10.1080/10428194.2020.1772475
   PubMed Web of Science ®Google Scholar
• Goldman-Mazur S, Kumar SK. Current approaches to management of high-risk multiple myeloma. Am J Hematol. 2021 Jul 1;96(7):854–871. doi:10.1002/ajh.26161
   PubMed Web of Science ®Google Scholar
• Costa LJ, Iacobelli S, Pasquini MC, et al. Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation. Bone Marrow Transplant. 2020 Sep;55(9):1810–1816. doi:10.1038/s41409-020-0887-4
   PubMed Web of Science ®Google Scholar
• Cavo M, Salwender H, Rosiñol L, et al. Double vs single autologous stem cell transplantation after bortezomib-based induction regimens for multiple myeloma: an integrated analysis of patient-level data from phase European III studies. Blood. 2013;122(21):767. doi:10.1182/blood.V122.21.767.767
   Google Scholar
• Hari P, Pasquini MC, Stadtmauer EA, et al. Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM). J Clin Oncol. 2020 May 20;38(15_suppl[May 20, 2020]):8506–8506. 10.1200/JCO.2020.38.15_suppl.8506.
   Google Scholar
• Schilling G, Hansen T, Shimoni A, et al. Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma. Leukemia. 2008 Jun;22(6):1250–1255. doi:10.1038/leu.2008.88
   PubMed Web of Science ®Google Scholar
• Yin X, Tang L, Fan F, et al. Allogeneic stem-cell transplantation for multiple myeloma: a systematic review and meta-analysis from 2007 to 2017. Cancer Cell Int. 2018;18:62. doi:10.1186/s12935-018-0553-8
   PubMed Web of Science ®Google Scholar
• Knop S, Engelhardt M, Liebisch P, et al. Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis. Leukemia. 2019 Nov;33(11):2710–2719. doi:10.1038/s41375-019-0537-2
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. J Clin Epidemiol. 2021 Jun;134:178–189. doi:10.1016/j.jclinepi.2021.03.001
   PubMed Web of Science ®Google Scholar
• Hagen P, Zhang J, Barton K. High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions. Blood Cancer J. 2022 May 30;12(5):83. doi:10.1038/s41408-022-00679-5
   PubMed Web of Science ®Google Scholar
• Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015 Sep 10;33(26):2863–2869. doi:10.1200/JCO.2015.61.2267
   PubMed Web of Science ®Google Scholar
• Chng WJ, Dispenzieri A, Chim CS, et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014 Feb;28(2):269–277. doi:10.1038/leu.2013.247
   PubMed Web of Science ®Google Scholar
• Sterne JA, Hernan MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. Br Med J. 2016 Oct 12;355:i4919. doi:10.1136/bmj.i4919
   PubMed Web of Science ®Google Scholar
• Guyot P, Ades AE, Ouwens MJ, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012 Feb 1;12:9. doi:10.1186/1471-2288-12-9
   PubMed Web of Science ®Google Scholar
• Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F, et al. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods. 2006 Jun;11(2):193–206. doi:10.1037/1082-989X.11.2.193
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions. Chichester (UK): John Wiley & Sons; 2019.
   Google Scholar
• Garban F, Attal M, Michallet M, et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood. 2006 May 1;107(9):3474–3480. doi:10.1182/blood-2005-09-3869
   PubMed Web of Science ®Google Scholar
• Giralt S, Costa LJ, Maloney D, et al. Tandem autologous-autologous versus autologous-allogeneic hematopoietic stem cell transplant for patients with multiple myeloma: long-term follow-up results from the blood and marrow transplant clinical trials network 0102 trial. Biol Blood Marrow Transplant. 2020 Apr;26(4):798–804. doi:10.1016/j.bbmt.2019.11.018
   PubMed Web of Science ®Google Scholar
• Krishnan A, Pasquini MC, Logan B, et al. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol. 2011 Dec;12(13):1195–1203. doi:10.1016/S1470-2045(11)70243-1
   PubMed Web of Science ®Google Scholar
• Moreau P, Garban F, Attal M, et al. Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma. Blood. 2008 Nov 1;112(9):3914–3915. doi:10.1182/blood-2008-07-168823
   PubMed Web of Science ®Google Scholar
• Gagelmann N, Eikema DJ, Koster L, et al. Tandem autologous stem cell transplantation improves outcomes in newly diagnosed multiple myeloma with extramedullary disease and high-risk cytogenetics: a study from the chronic malignancies working party of the European society for blood and marrow transplantation. Biol Blood Marrow Transplant. 2019 Nov;25(11):2134–2142. doi:10.1016/j.bbmt.2019.07.004
   PubMed Web of Science ®Google Scholar
• Gagelmann N, Eikema DJ, de Wreede LC, et al. Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT. Bone Marrow Transplant. 2021 Jan;56(1):210–217. doi:10.1038/s41409-020-01007-w
   PubMed Web of Science ®Google Scholar
• Knop S, Liebisch P, Hebart H, et al. Autologous followed by allogeneic versus tandem-autologous stem cell transplant in newly diagnosed FISH-del13q myeloma. Washington (DC): American Society of Hematology; 2014.
   Google Scholar
• Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998 Sep;102(5):1115–1123.
   PubMed Web of Science ®Google Scholar
• Rosinol L, Perez-Simon JA, Sureda A, et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood. 2008 Nov 1;112(9):3591–3593. doi:10.1182/blood-2008-02-141598
   PubMed Web of Science ®Google Scholar
• Bruno B, Rotta M, Patriarca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med. 2007 Mar 15;356(11):1110–1120. doi:10.1056/NEJMoa065464
   PubMed Web of Science ®Google Scholar
• Giaccone L, Storer B, Patriarca F, et al. Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. Blood. 2011 Jun 16;117(24):6721–6727. doi:10.1182/blood-2011-03-339945
   PubMed Web of Science ®Google Scholar
• Armeson KE, Hill EG, Costa LJ. Tandem autologous vs autologous plus reduced intensity allogeneic transplantation in the upfront management of multiple myeloma: meta-analysis of trials with biological assignment. Bone Marrow Transplant. 2013 Apr;48(4):562–567. doi:10.1038/bmt.2012.173
   PubMed Web of Science ®Google Scholar
• Kharfan-Dabaja MA, Hamadani M, Reljic T, et al. Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. J Hematol Oncol. 2013 Jan 4;6:2. doi:10.1186/1756-8722-6-2
   PubMed Web of Science ®Google Scholar
• Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007 Jun 7;8:16. doi:10.1186/1745-6215-8-16
   PubMed Web of Science ®Google Scholar
• Kumar SK, Rajkumar SV. The multiple myelomas – current concepts in cytogenetic classification and therapy. Nat Rev Clin Oncol. 2018 Jul;15(7):409–421. doi:10.1038/s41571-018-0018-y
   PubMed Web of Science ®Google Scholar
• Lokhorst HM, Schattenberg A, Cornelissen JJ, et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol. 2000 Aug;18(16):3031–3037. doi:10.1200/JCO.2000.18.16.3031
   PubMed Web of Science ®Google Scholar
• Mateos MV, Martínez BP, González-Calle V. High-risk multiple myeloma: how to treat at diagnosis and relapse? Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):30–36. doi:10.1182/hematology.2021000229
   PubMedGoogle Scholar